

EMERGING MARKETS: Covid-19 Vaccination Strategies and Challenges

Our Covid-19 vaccination table includes updated information on the immunization strategies selected EMs are pursuing and the challenges they face.

Below are some of this week's key developments. Please do not hesitate to contact us if you want to discuss any of the countries mentioned in more detail.

Click on 'View PDF' to see the table.

HIGHLIGHTS

Vaccine rollout

- Amid a continuing shortage of second doses of the Sputnik V vaccine, **Argentina** is analyzing whether AstraZeneca (AZ), Sinopharm and CanSino vaccines can be used on people who have received a first dose of the Sputnik V vaccine.
- **Colombia's** vaccination program exceeded its target of administering 17mn doses by the end of June; the delivery of US-donated single-shot Johnson & Johnson (J&J) vaccines should help the government meet its new target to apply 25mn doses by end-July.
- **Mexico's** President Andres Manuel Lopez Obrador (AMLO) has reiterated his promise that every adult will have been offered at least one vaccine dose by October.
- In **Peru**, 26% of the population over 60 has still not received even a single vaccine dose; the government is working on plans to increase vaccine uptake, including house-to-house visits.
- In **Russia**, compulsory vaccination of certain occupational groups is accelerating the rollout. More than 6mn (out of 26mn) people got their first doses during the past two weeks; however, 54% of residents are still not willing to get vaccinated.
- In **Brazil**, the government hopes to immunize the whole adult population by the end of 2021. Regional governments are targeting unvaccinated and misinformed communities.

Vaccine procurement

- **South Africa** is reconsidering acquiring AZ vaccines (earlier abandoned in favor of J&J and Pfizer-BioNTech (Pfizer) vaccines), while health regulator SAHPRA has authorized Sinovac's CoronaVac and is reviewing the Sputnik V and Sinopharm vaccines.
- The **World Bank** has approved an additional USD 130mn financing for Kenya to help the country procure more vaccines via the African Vaccine Acquisition Task Team (AVATT) and COVAX facilities.

- **Argentina's** President Alberto Fernandez has signed a decree to overcome regulatory and legal hurdles that have hindered the acquisition of US-made vaccines such as Pfizer and Moderna.

Infections and new variants

- The spread of the Delta variant is behind a new Covid-19 wave in many countries, including the **UK, Indonesia, Thailand, Russia, Iran, Bangladesh, Portugal, South Africa** and **Kenya**. In countries where the vaccine rollout has been slower, the increase in hospital admissions and deaths will most likely be followed by a tightening of lockdowns.
- In **Chile**, where the first cases of the Delta variant have been confirmed, President Sebastian Pinera has said that there are sufficient stocks of vaccines to administer third "booster" doses should they prove necessary.
- **South Korea** has hit a six-month-high in cluster infections with increasing variants; 80% of these cases are in Seoul and contact tracing is more challenging with less than a third being successful.

Vaccine diplomacy

- **South Africa's** Aspen Pharmacare will receive EUR 600mn from an International Finance Corporation (IFC) consortium, in partnership with US, French and German development finance institutions, to spur the development of vaccine manufacturing capacity in Africa. Aspen is now expected to produce 250mn J&J vaccine doses by year-end.
- **South Africa** is due to receive a donation of 1mn Pfizer doses from the US within the next few weeks.
- Amid slowing vaccination progress at home, **Hungary** has donated a total of 300,000 Sinopharm doses to **Montenegro** and **Bosnia & Herzegovina**.
- A leaked government memo about the possible need for booster shots for those who received the Sinovac vaccine is generating public complaints in **Thailand** of a lack of transparency. Officials say they did not want to undermine perceptions of the Chinese vaccine.

Client Portal >>

Macro Research
+44 20 7186 8894
Macro@teneo.com

© 2021 Teneo. All rights reserved. This material was produced by Teneo for use solely by the recipient. This communication is intended as general background research and is not intended to constitute advice on any particular commercial investment or trade matter or issue and should not be relied upon for such purposes. The views expressed here represent opinions as of this date and are subject to change without notice. The information has been obtained from sources believed to be reliable but no guarantees can be given as to its accuracy, completeness or reliability. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic or otherwise, without the prior consent of Teneo.

Emerging Markets Covid-19 Vaccination Strategies and Challenges

Rating of countries' vaccine rollout (as of 7 July 2021):

	Between 0% and 10% of the total population have received at least one Covid-19 vaccine dose
	Between 10% and 30% of the total population have received at least one Covid-19 vaccine dose
	More than 30% of the total population have received at least one Covid-19 vaccine dose

	Vaccination strategy	Current state of vaccine roll-out	Procurement
Israel	Majority of all adults vaccinated. More than one-third of the youth aged 10-19 have received the first dose.	Israel has one of the highest vaccination rates in the world, with 122 doses per hundred people. As of 6 Jul, 65.63% of the population has been fully vaccinated (about 80% of adults), and daily vaccination rates have trended downward as the eligible population diminishes. WHO estimates 306,000 Palestinians in West Bank and Gaza have been vaccinated (about 6%); 230,000 have been fully vaccinated, including 110,000 Palestinians who work in Israel and received Israeli vaccinations.	Pfizer-BioNTech – Israel is administering the Pfizer vaccine, in exchange for giving Pfizer extensive patient data. Moderna – Israel plans to vaccinate about 100,000 Palestinian workers with the Moderna vaccine. The Palestinian Authority has received more than 390,000 doses: 100,000 Sinopharm , 97,000 AZ SK Bio , 90,000 Sputnik V , 140,000 Pfizer-BioNTech and 2,000 Moderna , 25,000 AZ SII , and 48,000 AZ R-Pharm .
UAE	Emirati citizens, their domestic workers, elderly, sick, and those in health and education are eligible for vaccination without appointment. Other residents eligible for vaccination free of charge.	As of 5 July, 15.6mn shots have been administered (156% of population). The UAE has not reported how many are fully vaccinated since Feb. Third shots of Sinopharm drug are being given to those with low levels of antibodies. Dubai has emphasized the Pfizer vaccine, Abu Dhabi the Sinopharm vaccine.	Sinopharm and Pfizer-BioNTech are the two approved vaccines. UAE signed an agreement to produce Sinopharm domestically.
Chile	Target to vaccinate 80% of population over 16 years of age has been met. Medical workers were the first to receive vaccinations, followed by elderly in care homes; over 65s; key workers in public bureaucracy; people with other co-morbidities. Vaccinations (Pfizer-BioNTech vaccine) are currently being administered to 16-17-year-olds.	Pfizer vaccinations started in late Dec but mass campaign using China's Sinovac vaccine started 3 Feb. As of 3 Jul, 12.87mn people (67.3% of population) have received one vaccine dose and 10.87mn (56.9% of population) have received a double dose or a single-shot vaccine.	Pfizer-BioNTech – agreement for 10mn doses; Sinovac – agreement for 60mn doses over three years; AZ – agreement for 14.4mn doses. COVAX – agreement for 8mn doses. CanSino – agreement for 1.8mn doses. J&J – regulatory clearance in early June. Local regulatory approval for Sputnik V vaccine pending.
Hungary	Vaccination is available to all citizens as well as foreigners living in Hungary. Vaccinations of adolescents (12-15-year-olds) started in June. In July, the country started vaccinating its citizens abroad. There is no official vaccination target.	Vaccination started on 26 Dec. As of 6 Jul, 5.5mn people (56.6% of population) have received at least one jab and 5.07mn (52%) have received both shots. New vaccinations remain slow. The government is donating vaccines to other European countries.	Procurement contracts and deliveries as of 6 Jul via the EU's joint mechanism: AZ – 6.5mn doses (2.3mn delivered) Moderna – 1.7mn doses (861,805 delivered). Pfizer-BioNTech – 10.9mn doses (6.1mn delivered). J&J – 4.3mn doses (349,200 delivered). CureVac – 500,000 doses. National-level procurement: Sputnik V – 2mn doses (delivered). Sinopharm – 5mn doses (5.2mn delivered).
Singapore	Seniors, healthcare and frontline workers nominated by their employers were the first eligible groups. Vaccination of 40-year-olds is ongoing, and Singapore is phasing in younger groups as supply becomes available.	As of 5 Jul, 5.86mn doses have been administered. So far, 2.19mn (38.5% of the population) have been fully vaccinated and 1.47mn (26%) are on their first shot. The goal is to complete all immunizations by the end of the year.	Government has concluded agreements with three suppliers, with undisclosed quantities: Pfizer-BioNTech , Moderna and Arcturus . It has received Coronavac but claims data for authorization is incomplete. It is looking for additional supplies in anticipation of possible shortfalls.

	Vaccination strategy	Current state of vaccine roll-out	Procurement
Poland	Adults of all age groups are allowed to register for a Covid-19 jab. Vaccination is also available for adolescents aged over 12. To facilitate vaccinations during the summer holiday period, residents may receive second doses at a different vaccination site than the first one. Starting 1 Jul, vaccinated residents can participate in a state-run lottery.	Vaccinations started on 27 Dec. As of 6 Jul, 17.1mn residents (44.9% of population) received a first jab and 13mn (34.0%) had both shots. The country aims to achieve sufficient immunity levels to control the pandemic by year-end.	Procurement exclusively via the EU. Overall, around 100mn doses contracted. As of 6 Jul, 39.8mn vaccine doses delivered: 27.5mn Pfizer-BioNTech , 7.0mn AZ , 3.8mn Moderna , 1.5mn J&J .
Greece	Currently offering full range of vaccines to everyone over 18. Government recently introduced a financial incentive for 15-24 age group by offering them a EUR 150 prepaid card if they get vaccinated. The authorities would like to have 70-75% of the adult population vaccinated by end of summer, compared to 56% currently.	As of 5 Jul, Greece had administered more than 9mn vaccines, resulting in 46.9% of the total population having received at least one jab and 37.5% being fully vaccinated. Daily vaccination rates have fallen below 100,000 in recent weeks.	Greece is using Pfizer-BioNTech , AZ , Moderna and J&J vaccines, under the EU's procurement process. It expects to receive another 1.5mn Pfizer jabs in Jul and 1.1mn in Aug. Next-day appointments for J&J and Moderna vaccines are available in most of Greece, rising to three days for Pfizer .
China	Goal of fully vaccinating 560mn people, or 40% of the population, by end-June appears to have been met, though government has not disclosed exact figures. The Chinese Centre for Disease Control and Prevention (CDC) said 80-85% vaccination is required to reach herd immunity and that this level could be reached by end-2021. The CDC is also studying booster shots to increase effectiveness against variants.	As of 5 Jul, China had administered 1.32bn doses (equal to 92% of population but includes second doses) at an average daily pace of 16mn doses over previous week. Recent outbreaks in Anhui, Liaoning, and Guangzhou provinces have contributed to a decline in vaccine hesitancy.	Regulators have approved five domestic vaccines; Sinopharm Beijing , Sinopharm Wuhan , CanSino Biologics , Sinovac Biotech , and Anhui Zhifei Longcom Biopharmaceuticals . Fosun Pharmaceutical reached a deal with BioNTech to build a factory in Shanghai to produce Pfizer-BioNTech vaccines.
Saudi Arabia	Health Ministry set up 587 vaccine centers across the country. Saudi Arabia approved the use of two different Covid-19 vaccines for the first and second dose to speed up the program. New regulations and fines in place to limit spread during Hajj pilgrimage season from 17-22 July. Proof of vaccination required for many public events and activities from 1 Aug.	The vaccination program began on 17 Dec. As of 6 Jul, the Kingdom has administered 18.6mn vaccine doses; 53% of the population has received at least one dose. Pfizer has been approved for 12-18-year-olds.	Pfizer-BioNTech , Moderna , J&J , and AZ approved for administration. Government has secured an unknown number of Sputnik V doses.
Czech Republic	Since 1 Jul, all residents aged over 12 are eligible for vaccination. In Jul, the government plans to set up vaccination centers which would allow residents to show up without pre-registration.	Vaccinations started on 27 Dec. As of 6 Jul, 5mn residents (47% of population) have received a first jab and 3.4mn (32.1%) have received both shots. 81% of immunizations carried out with Pfizer-BioNTech vaccine; 9% with AZ ; 9% with Moderna and 1% with J&J .	Procurement has been conducted exclusively via the EU. As of 6 Jul, a total of 9.74mn doses of vaccines delivered: Pfizer-BioNTech – 7mn; Moderna – 785,100; AZ – 805,200; J&J – 150,000.
Turkey	Vaccination program divided into four stages, starting with medical personnel, pharmacy workers and those over 65, followed by security forces personnel, teachers, workers in food industry and transportation, and then Stages 2 and 3, the 50-64 and 18-49 age groups, respectively. On 25 Jun, Turkey began vaccinating segment B6, the 18-24 age group, of Stage 3. Government aims to vaccinate all adult residents by Sep. On 1 Jul, it began offering third doses to those in high-risk groups amid concerns over the Sinovac vaccine's effectiveness against the Delta variant.	Vaccine rollout started on 13 Jan with Sinovac . On 2 Apr, vaccinations also began with Pfizer-BioNTech vaccine. As of 6 Jul, 54.12mn doses had been administered, with 36.41mn (43.5% of population) people having received a first dose and 15.96mn (19.1% of population) two doses. Fresh Pfizer-BioNTech deliveries resulted in a rapid vaccine acceleration in Jun, which has continued in Jul.	Sinovac – agreement for 100mn doses, of which 34.5mn delivered by 6 Jul. Pfizer-BioNTech – agreement for 120mn doses, with 30mn delivered by early Jul. Sputnik V – agreement for 50mn doses. 0.4mn doses arrived in late Jun but none had been administered as of 6 Jul. Turkey has not joined COVAX .

	Vaccination strategy	Current state of vaccine roll-out	Procurement
Brazil	<p>Phase 1: health workers; indigenous communities in demarcated territories; over 60s in care institutions; over 75s.</p> <p>Phase 2: 60-74s seniors.</p> <p>Phase 3: persons with comorbidities.</p> <p>Phase 4: education workers, homeless population, security and rescue forces, others.</p> <p>Phase 5: 59-18 gradually.</p>	<p>As of 6 Jul, 76.4mn first doses have been administered (representing 36.1% of the population) while 27.1mn people (12.8% of population) have received two doses.</p>	<p>AZ – 100.4mn doses to be delivered in Jul, 210mn by year-end.</p> <p>CoronaVac – 10mn doses expected in Jul. Another 130mn doses by year-end.</p> <p>Pfizer – 15mn doses expected in Jul; 100mn by year-end.</p> <p>J&J – 38mn doses expected in Q4.</p> <p>Sputnik V – On 4 Jun, ANVISA (health regulator) approved conditional import for 9 states. 10mn doses expected by year-end.</p> <p>Covaxin – Contract suspended.</p> <p>COVAX – minimum 10% of population quota (42mn) doses. WHO to provide 10-14mn doses for distribution from mid-Feb to Jun. 2mn AZ expected in Jul.</p> <p>ButanVac – currently in trial; 100mn expected by year-end.</p>
Argentina	<p>Health sector personnel first in line for vaccine, followed in descending order by over 70s; over 60s; security personnel; vulnerable and at-risk in 18-59 age range; education sector; and strategic or vulnerable groups.</p>	<p>Sputnik V vaccinations started on 29 Dec. As of 6 Jul, 18.24mn first doses have been administered (representing 40.6% of population) while 4.6mn people (10.2% of population) have received two doses.</p>	<p>Sputnik V – agreement for 30mn doses; local production set for imminent start.</p> <p>AZ – contract for 23.6mn doses, though most to be produced locally in conjunction with Mexico.</p> <p>Sinopharm – agreement for 24mn doses.</p> <p>CanSino – 5.4mn doses ordered; arrival expected over Jul.</p> <p>COVAX – approx. 1.9mn doses delivered; government has been criticized for ordering only 20% of its entitlement.</p>
South Korea	<p>Vaccination campaign started on 26 Feb. Goal to vaccinate 13mn people, or 25% of population, with two doses by end-June and 70% with two doses by Nov 2021.</p>	<p>As of 5 Jul, 19.4mn doses administered. 10% of population have been fully vaccinated; 30% of the population have received at least one dose.</p> <p>AstraZeneca jabs are administered only to the 50yrs+ age group. The military has begun providing 2nd Pfizer-BioNTech jabs to personnel aged under 30, supported by a US donation of 1mn vaccines delivered in Jun. Samsung and other large companies will launch in-house vaccination programs in Aug. High schools will be vaccinated from 19 Jul; daycare centers, primary and middle schools from 28 Jul.</p>	<p>The government has signed agreements to procure vaccines to inoculate the entire population twice, but many deliveries are delayed until Q3 or Q4, creating a summer shortfall. A swap-deal with Israel will result in delivery of 700,000 soon-to-expire Pfizer-BioNTech doses in early Jul, in exchange for the same amount being returned in Sep/Oct.</p> <p>AZ – 20mn doses</p> <p>Pfizer-BioNTech – 20mn doses, 2.6mn additional doses delivered by end-Jun.</p> <p>Moderna – 40mn doses.</p> <p>J&J – 6mn doses.</p> <p>COVAX – 20mn doses.</p> <p>Novavax – production began in Apr 2021, 20mn doses to be rolled out by Sep 2021.</p>
India	<p>From 1 May, everyone above 18 became eligible for vaccination. From 21 Jun, all vaccines from government health facilities have been declared free of cost. The federal government, now alone now in charge of vaccinations, is allocating vaccine supplies to states according to demand assessments. All import curbs on foreign vaccines have been lifted and import duties have been waived. While the target to vaccinate everybody above 45 without comorbidities has yet to be met, the vaccination process has picked up pace.</p>	<p>Vaccine rollout began 16 Jan. As of 4 Jul, India had administered 347.3mn vaccine doses in total (20.6% of population). 62.92mn people are fully vaccinated (4.6% of population). The rate of new Covid-19 infections is dropping. India has halted AZ vaccine exports to cater to domestic demand. Exports of Remdesivir and diversion of oxygen to non-medical uses have been banned. Some taxes on inputs in vaccine manufacture have been lowered.</p>	<p>All vaccines now free to be used in India, whether Indian or foreign, as long as they have been certified as safe in the country of origin. Import duties have been waived. However, Pfizer is negotiating an assurance of indemnity before it supplies vaccines to India. Russia's Sputnik V is available since Jun. Both Pfizer-BioNTech and Moderna have announced that they will supply vaccines only to federal government rather than state governments directly. Vaccine supplies have improved dramatically after the federal government took charge. However, some states are noticing supply chain glitches.</p>

	Vaccination strategy	Current state of vaccine roll-out	Procurement
Mexico	Frontline medical workers first in line followed by the over 60s age cohort and then in descending order by age. Government wants all adults to have been offered at least one dose by Oct.	Vaccinations started 24 Dec. Rollout stalled mid-Jan to mid-Feb but subsequently resumed with new vaccines from wider array of suppliers. As of 4 Jul, 32.58mn people (25.3% of population) had received one vaccine dose, with 19.83mn people (15.4% of population) fully inoculated.	AZ – agreement for 77.4mn doses. US has supplied Mexico with 2.7mn additional AZ doses. Pfizer – 34mn doses ordered; 22mn delivered as of 4 Jul. CanSino – 35mn doses agreed. Sputnik V – agreement for 24mn doses, with local production expected soon. COVAX – 51.5mn doses agreed; Sinovac – agreement for 20mn doses. J&J – 1.35mn doses delivered. Sinopharm – agreement for 12mn doses though local regulatory clearance pending.
Colombia	Plan is to vaccinate 70% of the population (35mn people) by end-2021. Medical personnel first in line, followed by elderly and clinically vulnerable. June target of administering 17mn doses was exceeded; latest target is to apply 25mn jabs by end-July.	Vaccination campaign started on 17 Feb with Pfizer vaccine. As of 5 Jul, 19.26mn doses applied. This includes 7.28mn people (14.5% of population) who have received two doses and 240,000 who have received the single-shot J&J vaccine.	Pfizer-BioNTech – agreement for 15mn doses. AZ – 10mn doses agreed. J&J – agreement for 9mn doses; local regulatory clearance granted. Sinovac – agreement for 10mn doses. Moderna – agreement for 10mn doses. COVAX – agreement for 20mn doses.
Russia	Vaccination available to all citizens aged 18 and above. Immunization target: 68.6mn people (60% of adult population). In multiple regions, authorities are introducing compulsory vaccination for certain occupational groups (employees in state institutions and companies, workers in services sector etc.). Some regions are starting revaccination of residents inoculated six months ago or more.	Vaccinations started in early Dec. As of 6 Jul, an estimated 26.1mn residents (17.8% of population) had received at least one jab and 18.2mn (12.5% of population) were fully vaccinated. Compulsory vaccination is speeding up the process, but 54% of population is still reluctant to get vaccinated.	Russia relies solely on domestically developed vaccines: Sputnik V , EpiVac , CoviVac and Sputnik Light . Government expects Sputnik V production outside Russia to reach 5-6mn doses per month starting Jul.
Indonesia	Frontline healthcare workers estimated at 1.3mn have been vaccinated first, followed by security personnel and 17mn teachers; working age 15-59 are also now being vaccinated, simultaneously with the elderly. Vaccines procured by central government; distributed for free but not mandatory. Government is allowing the private sector to purchase vaccines for their employees, and such vaccination has started.	Second vaccination phase has started, focusing on the elderly and active workforce. As of 5 Jul, a total of 46.33mn shots had been administered, with 14.04mn (5.19% of the population) fully vaccinated and another 18.27mn (6.75%) on their first jab. Pace could accelerate starting in September as more supplies are expected.	Sinovac – 125mn doses; Pfizer-BioNTech – 100mn doses; Novavax – 100mn doses; COVAX initiative – 100mn doses; AZ – 100mn doses; private sector importation unknown.
Peru	Phase 1 focused on medical and other frontline emergency personnel, including election staff. Phase 2 focused on over 60s, those with co-morbidities, and indigenous population. Caretaker government has revised down its original goal and now wants 4.65mn people vaccinated by 28 Jul, when handover to new government is scheduled; government also says it will leave sizeable stock of vaccines for incoming government.	Nov 2020 political crisis interrupted procurement process, but caretaker government accelerated efforts from early 2021. Vaccinations using Sinopharm vaccine started 9 Feb. Pfizer-BioNTech vaccines now also being administered. As of 4 Jul, 4.78mn first doses have been administered (representing 14.7% of population). 3.35mn people (10.3% of population) have received two doses.	Sinopharm – contract for 38mn doses. AZ – agreement for 14.4mn doses to arrive from Sep. Pfizer-BioNTech – original agreement for 20mn doses expanded to 32mn doses. COVAX – agreement for 13.2mn doses. Ongoing talks with J&J (5mn doses), Russia's Gamaleya Institute (for 10mn Sputnik V doses), Moderna (12mn doses), Sinovac (7mn doses), and CureVac .
Malaysia	Frontline medical workers, police and army officials are being prioritized in phase one of the vaccine rollout. Phase two, which started 19 Apr and will run through Aug, will target senior citizens, high-risk groups with co-morbidities and the disabled. Third phase that started in May included all adults above 18.	As of 5 Jul, a total of 9.33mn shots have been administered, with 2.74mn (8.6% of population) fully vaccinated and another 3.85mn (12.05%) still on their first shot.	Pfizer-BioNTech – 32mn doses; Sinovac – 12mn doses; AZ – 6.4mn doses via COVAX facility and another 6.4mn contracted directly; Sputnik V – 6.4mn doses; CanSino Biologics – 3.5mn doses

	Vaccination strategy	Current state of vaccine roll-out	Procurement
Thailand	Phase one prioritizes the elderly, frontline healthcare and social workers, and those with co-morbidities. Phase two will focus on provinces with highest Covid-19 incidence. However, there are two special cases – companies will be allowed to import and distribute vaccines, and tourism areas such as Phuket are being prioritized.	Uneven supplies of locally-produced AZ vaccines sometimes slow down vaccine rollout. Sinovac and Sinopharm vaccines are now being imported. As of 4 Jul, a total of 10.77mn shots have been administered, with 2.97mn (4.27%) having been fully vaccinated and 4.83mn (6.94%) on their first jab.	Sinovac – 2mn, but Thailand is negotiating for an additional 6mn doses. AZ – 61mn (imported and local joint venture).
Philippines	Vaccine rollout started in Mar with high-risk groups such as healthcare workers; workers in education, social welfare agencies; law enforcement and military personnel; the poor; senior citizens; other vulnerable populations. Private sector is allowed to import vaccines, though some are required to make counterpart donations. Private-sector importation may make up the bulk of Q2 and Q3 vaccinations. In Manila, citizens whose work requires them to leave their homes are now being vaccinated.	As of 4 Jul, a total of 11.71mn shots have been administered, with 2.87mn (2.65%) of the population fully vaccinated and 5.97mn (5.52%) still on their first shot. Shortages in supply are being felt as of early July, and may take several weeks to resolve.	The Philippine government has ordered 113mn doses from five vaccine manufacturers: Sinovac – 26mn doses, Sputnik V – 10mn, Moderna – 20mn, AZ – 17mn, Pfizer – 40mn. Several million Novavax doses imported by the private sector are expected in the Q4.
Kenya	Kenya plans to inoculate 10mn citizens by end-2021 and entire adult population (26mn) by end-2022. Priority given to frontline medical workers, elderly, essential workers (police, teachers, students, immigration officials), workers in hospitality sector, people with comorbidities, people in informal settlements.	First 1.02mn AZ/COVAX vaccine doses arrived 2 Mar. Rollout began 5 Mar, but supplies were nearly exhausted by Jun as India's export restrictions delayed further AZ/COVAX deliveries. As of 4 Jul, vaccination levels had plateaued at 1.89% of population.	Kenya is reliant on COVAX (24mn doses). AZ vaccines donated by India (100,000), Denmark (358,700), South Sudan (72,000), DRC (70,000). Amid COVAX delays, government has ordered 13mn J&J vaccines (to start arriving from Aug). Additional orders planned, with IFC financing, under the African Vaccine Acquisition Task Team (AVATT) initiative.
Egypt	Vaccine registration opened to the general public on 6 Mar before millions of at-risk citizens had been vaccinated. The rollout has been criticized for lack of clear strategy and transparency, which in turn has created delays, and failed to reach certain priority groups and address vaccine hesitancy concerns. Egypt announced on 3 Jul that it had signed contracts for 120mn vaccine doses, and would start inoculating the population with the locally-produced Sinovac vaccine beginning in Aug.	As of 4 Jul, Egypt had administered 4.5mn shots, representing 3.6% of the population (0.9% of the population has been fully vaccinated). Egypt aims to vaccinate 40% of its 100mn population by end-2021. Egypt has been charging patients for vaccinations, in contravention of global trends, and reports show that Egypt has undercounted Covid-19 deaths by a factor of more than 12.	COVAX – agreement for 20mn doses of AZ vaccine. Sinopharm – agreement for 40mn doses; 350,000 reportedly received. Pfizer-BioNTech – contracts reportedly signed for 20mn. AZ – agreement for 30mn doses Sputnik V – 25mn have been secured. Egypt has also signed agreements to manufacture Sputnik V and Sinovac vaccines domestically; production of 60mn Sinovac doses was due to start in Jun.
Taiwan	Priority groups (868,000 people): health care personnel; essential workers; nursing home staff; military personnel; social welfare workers. Outside priority groups, individuals can obtain a limited supply of vaccinations through a self-paid program if they intend to travel abroad (excluding tourism).	As of 5 Jul, 2.53mn first doses administered (10.6% of population) and 48,000 second doses (0.2% of population). Daily pace of 102,000 over the last week.	20mn doses ordered; 5.3mn doses received through early Jul, mostly donations from the US on 20 Jun (2.5mn Moderna) and Japan on 4 Jun (1.24mn AZ). COVAX provided an additional 609,000 AZ doses. Two large tech companies, Hon Hai and TSMC, are reportedly negotiating to purchase 5mn BioNTech doses from Shanghai Fosun Pharmaceutical.
South Africa	Plans to vaccinate 40mn people by Feb 2022, but rollout slow. Phase 1: ca. 1.25mn frontline medical workers; Phase 2: people over 60; vaccination of teachers and police expedited, while originally planned vaccination of those with comorbidities delayed; Phase 3: remaining adult population.	Limited "implementation study" rollout of J&J vaccine started on 18 Feb. Phase 2 started on 17 May, reliant on J&J and Pfizer vaccines. Pfizer vaccines arriving in large quantities, but J&J vaccines held up by US FDA investigation. As of 4 Jul, 5.59% of population had received at least one shot.	South Africa pivoted from relying on COVAX/AZ vaccines to two manufacturers, J&J and Pfizer. Deliveries ramped up from May but largest volumes due in Q3/4. J&J – 31mn doses Pfizer-BioNTech – 30mn doses Authorities now reconsidering acquiring AZ vaccines; health regulator SAHPRA has authorized Sinovac's CoronaVac vaccine and is reviewing Sinopharm and Sputnik V vaccines.

	Vaccination strategy	Current state of vaccine roll-out	Procurement
Pakistan	Vaccination of 18-year-olds and above commenced on 3 Jun. Vaccine registration for over-40s opened on 27 Apr. Meanwhile, walk-in vaccination is available for those above 50. Those above 65 and frontline workers are still being vaccinated. The country is reporting a fall in positivity rates and a decline in new infections. It aims to vaccinate 70mn people by Dec 2021.	As of 4 Jul, 17.39mn doses have been administered and 3.36mn people are fully vaccinated (1.5% of the population).	Emergency use permission given to AZ , Sinopharm and CanSino . Both Chinese vaccines are undergoing clinical trials. Four more vaccines in the pipeline. First COVAX vaccines have been received. Pakistan is working on developing a new nasal vaccine with CanSino , a Chinese manufacturer. On 4 Jun, it announced the successful manufacture of CanSinoBio , a single-dose vaccine produced with Chinese technology. On 21 Jun, Pfizer-BioNTech announced it will provide 13mn doses over the course of 2021.
Nigeria	Vaccination targets: 40% of population in 2021, 70% by end-2022. Healthcare personnel; people over 50; people with underlying health conditions to be prioritized. Most heavily affected states will be prioritized in allocation of doses.	First batch (3.9mn doses) of AZ vaccine supplied by COVAX arrived 2 Mar; second batch of similar volume expected by early Aug. As of 5 Jul, 3.83mn people (1.2% of population) had received their first jab.	20% of vaccines supposed to be supplied through the COVAX initiative. Government expects total of 58mn vaccine doses from COVAX (16mn) and the AVATT (42mn). Government also expressed interest in procuring Sputnik V and/or Sinovac/Sinopharm vaccines.

© 2021 Teneo. All rights reserved. This material was produced by Teneo for use solely by the recipient. This communication is intended as general background research and is not intended to constitute advice on any particular commercial investment or trade matter or issue and should not be relied upon for such purposes. The views expressed here represent opinions as of this date and are subject to change without notice. The information has been obtained from sources believed to be reliable but no guarantees can be given as to its accuracy, completeness or reliability. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic or otherwise, without the prior consent of Teneo.